ATE394474T1 - Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen - Google Patents
Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellenInfo
- Publication number
- ATE394474T1 ATE394474T1 AT98921011T AT98921011T ATE394474T1 AT E394474 T1 ATE394474 T1 AT E394474T1 AT 98921011 T AT98921011 T AT 98921011T AT 98921011 T AT98921011 T AT 98921011T AT E394474 T1 ATE394474 T1 AT E394474T1
- Authority
- AT
- Austria
- Prior art keywords
- antigen
- cells
- activated
- pbls
- loaded
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 210000000612 antigen-presenting cell Anatomy 0.000 title 1
- 210000000265 leukocyte Anatomy 0.000 abstract 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940030156 cell vaccine Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 210000003071 memory t lymphocyte Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4727—Mucins, e.g. human intestinal mucin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4256—Tumor associated carbohydrates
- A61K40/4257—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4594997P | 1997-05-08 | 1997-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE394474T1 true ATE394474T1 (de) | 2008-05-15 |
Family
ID=21940709
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98921011T ATE394474T1 (de) | 1997-05-08 | 1998-05-07 | Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen |
| AT05076809T ATE491465T1 (de) | 1997-05-08 | 1998-05-07 | Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05076809T ATE491465T1 (de) | 1997-05-08 | 1998-05-07 | Verfahren zur gewinnung aktivierter t-zellen und mit antigen-inkubierten antigen-präsentierender zellen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6600012B1 (https=) |
| EP (3) | EP2341072A3 (https=) |
| JP (1) | JP4480800B2 (https=) |
| AT (2) | ATE394474T1 (https=) |
| AU (1) | AU727863B2 (https=) |
| CA (1) | CA2289742C (https=) |
| DE (2) | DE69839443D1 (https=) |
| DK (1) | DK1634949T3 (https=) |
| ES (1) | ES2357960T3 (https=) |
| WO (1) | WO1998050527A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19906744A1 (de) * | 1999-02-18 | 2000-08-24 | Martin Roecken | Verfahren zur Herstellung antitumoraler Th1-Zellen |
| CA2368967A1 (en) * | 1999-04-09 | 2000-10-19 | Biomira, Inc. | Telomerase-specific cancer vaccine |
| DE19917195B4 (de) | 1999-04-16 | 2006-09-28 | Immatics Biotechnologies Gmbh | Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor |
| JP2003510094A (ja) * | 1999-09-08 | 2003-03-18 | トランジェーヌ、ソシエテ、アノニム | Ｍｕｃ−１由来のペプチド |
| GB9921337D0 (en) * | 1999-09-09 | 1999-11-10 | Axis Genetics Plc | Modified plant viruses |
| GB0007150D0 (en) * | 2000-03-24 | 2000-05-17 | Lamellar Therapeutics Limited | Immunotherapeutic methods and compositions |
| ES2424131T3 (es) * | 2001-03-27 | 2013-09-27 | Oncothyreon Inc. | Vacuna para modular respuestas inmunitarias entre T1 y T2 |
| IL164079A0 (en) | 2002-03-15 | 2005-12-18 | Us Dept Veterans Affairs | Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs |
| WO2003089574A2 (en) * | 2002-04-15 | 2003-10-30 | Biomira, Inc. | Synthetic glyco-lipo-peptides as vaccines |
| EP1537143A2 (en) * | 2002-09-05 | 2005-06-08 | Cell Center Cologne GmbH | Immunogenic muc1 glycopeptides |
| KR20050062605A (ko) * | 2002-10-10 | 2005-06-23 | 디파트먼트 오브 베테랑스 어페어스 오피스 오브 더 제네럴 카운셀 (024) | 종양 특이적 에피토프에 대해 지정된 표지된 활성화임파구를 이용한 종양의 검출, 위치결정 및 병기결정 |
| US20050045205A1 (en) * | 2003-08-29 | 2005-03-03 | Stach Steven R. | Apparatus and method for cleaning printed circuit boards |
| GB0322448D0 (en) | 2003-09-25 | 2003-10-29 | Lamellar Therapeutics Ltd | Using lamellar bodies to modify linear biological macro molecules |
| JP5060134B2 (ja) | 2003-12-12 | 2012-10-31 | ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ | ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ |
| TW201204410A (en) | 2004-04-01 | 2012-02-01 | Oncothyreon Inc | Mucinous glycoprotein (MUC-1) vaccine |
| EP1812052A1 (en) * | 2004-11-02 | 2007-08-01 | Biomedical Research Models, Inc. | Methods of cancer treatment/prevention using cancer cell-specific surface antigens |
| PL1896051T3 (pl) | 2005-06-28 | 2015-04-30 | Oncothyreon Inc | Sposób leczenia pacjentów szczepionką glikoproteiny mucynowej (muc-1) |
| WO2010002478A2 (en) | 2008-07-03 | 2010-01-07 | University Of Georgia Research Foundation, Inc. | Glycopeptide and uses thereof |
| EP1989326A4 (en) | 2006-01-17 | 2009-09-30 | Health Research Inc | BIO-HETERODUPLEX TRACKING TEST |
| RU2377994C1 (ru) * | 2008-05-21 | 2010-01-10 | Леонид Валентинович Загребин | Способ иммунореабилитации онкозаболеваний |
| WO2010030505A1 (en) * | 2008-09-10 | 2010-03-18 | Austin American Technology Corporation | Cleaning and testing ionic cleanliness of electronic assemblies |
| AU2011226992B2 (en) | 2010-05-10 | 2012-03-22 | Ascend Biopharmaceuticals Pty Ltd | Immunostimulatory and vaccine compositions |
| KR20140023903A (ko) | 2011-02-24 | 2014-02-27 | 온코타이레온, 인코포레이티드 | 항원보강제를 갖는 muc1 기초 당지질펩티드 백신 |
| EP2800762B1 (en) | 2012-01-03 | 2018-01-03 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Native and agonist ctl epitopes of the muc1 tumor antigen |
| CN105283199A (zh) | 2013-05-14 | 2016-01-27 | 默克专利股份公司 | 通过muc-1脂肽接种治疗肺癌的方法 |
| WO2015058831A1 (en) | 2013-10-25 | 2015-04-30 | Merck Patent Gmbh | Elevated biomarker expression in lung cancer patients responding to treatment with muc-1 lipopeptide vaccines |
| CN116970059A (zh) | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| IL269000B2 (en) | 2017-03-15 | 2024-06-01 | Cue Biopharma Inc | Methods for modulating an immune response |
| GB201812647D0 (en) | 2018-08-03 | 2018-09-19 | Chancellor Masters And Scholars Of The Univ Of Oxford | Viral vectors and methods for the prevention or treatment of cancer |
| JP2022536581A (ja) * | 2019-06-19 | 2022-08-18 | キュー バイオファーマ， インコーポレイテッド | 多量体ｔ細胞調節性ポリペプチド及びその使用方法 |
| TW202208395A (zh) | 2020-05-12 | 2022-03-01 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| EP4211149A4 (en) | 2020-09-09 | 2024-10-09 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2135068T3 (es) | 1994-06-13 | 1999-10-16 | Unilever Nv | Activacion de blanqueantes. |
| PT765386E (pt) * | 1994-06-14 | 2015-02-06 | Univ Leland Stanford Junior | Processos para a activação in vivo de células t, através de células dendríticas pulsadas com antigénio |
| WO1996022067A2 (en) * | 1994-12-27 | 1996-07-25 | United Biomedical, Inc. | Peptide ratchet libraries for ctl-inducing vaccines and therapeutics |
| AU6330896A (en) * | 1995-06-07 | 1996-12-30 | Governors Of The University Of Alberta, The | A method for eliciting a th1-specific immune response |
| EP1012276A2 (en) | 1997-02-24 | 2000-06-28 | Therion Biologics Corporation | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
-
1998
- 1998-05-07 ES ES05076809T patent/ES2357960T3/es not_active Expired - Lifetime
- 1998-05-07 CA CA2289742A patent/CA2289742C/en not_active Expired - Fee Related
- 1998-05-07 AT AT98921011T patent/ATE394474T1/de not_active IP Right Cessation
- 1998-05-07 EP EP10180388.0A patent/EP2341072A3/en not_active Withdrawn
- 1998-05-07 AT AT05076809T patent/ATE491465T1/de active
- 1998-05-07 DE DE69839443T patent/DE69839443D1/de not_active Expired - Lifetime
- 1998-05-07 DE DE69842060T patent/DE69842060D1/de not_active Expired - Lifetime
- 1998-05-07 AU AU73712/98A patent/AU727863B2/en not_active Ceased
- 1998-05-07 DK DK05076809.2T patent/DK1634949T3/da active
- 1998-05-07 EP EP05076809A patent/EP1634949B1/en not_active Expired - Lifetime
- 1998-05-07 JP JP54847798A patent/JP4480800B2/ja not_active Expired - Fee Related
- 1998-05-07 EP EP98921011A patent/EP0986636B1/en not_active Expired - Lifetime
- 1998-05-07 WO PCT/US1998/009288 patent/WO1998050527A1/en not_active Ceased
-
2000
- 2000-02-03 US US09/497,232 patent/US6600012B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2289742A1 (en) | 1998-11-12 |
| EP1634949A1 (en) | 2006-03-15 |
| CA2289742C (en) | 2013-07-16 |
| ES2357960T3 (es) | 2011-05-04 |
| EP2341072A3 (en) | 2013-10-30 |
| EP1634949B1 (en) | 2010-12-15 |
| DE69842060D1 (de) | 2011-01-27 |
| JP2001525668A (ja) | 2001-12-11 |
| US6600012B1 (en) | 2003-07-29 |
| EP2341072A2 (en) | 2011-07-06 |
| EP0986636B1 (en) | 2008-05-07 |
| DK1634949T3 (da) | 2011-03-28 |
| JP4480800B2 (ja) | 2010-06-16 |
| WO1998050527A1 (en) | 1998-11-12 |
| AU7371298A (en) | 1998-11-27 |
| DE69839443D1 (de) | 2008-06-19 |
| ATE491465T1 (de) | 2011-01-15 |
| AU727863B2 (en) | 2001-01-04 |
| EP0986636A1 (en) | 2000-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE394474T1 (de) | Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen | |
| ATE325802T1 (de) | Verfahren zur aktivierung von menschlichen, antigen-aktivierenden zellen, aktivierte menschliche, antigen-aktivierende zellen und anwendungen derselben | |
| ATE330002T1 (de) | Verfahren zur herstellung von membranvesikeln | |
| ATE506962T1 (de) | Von survivin abgeleitete peptide und deren verwendung | |
| NZ514228A (en) | Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation | |
| CY1109837T1 (el) | Διαγνωστικο και θεραπευτικο επιτοπιο | |
| ES2177964T3 (es) | Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores. | |
| IL219223B (en) | Non-naturally occurring antigen-presenting cells (nnapc) derived from drosophila melanogaster cells for use in preparing a suspension of cd8+ cells and methods for their manufacture | |
| GR880100198A (el) | Τμήματα DNA, πολυπεπτίδια και αντισώματα σχετιζόμενα προς τον παράγοντα ιστών του αν?ρώπου. | |
| ATE368054T1 (de) | Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität | |
| DE69942100D1 (de) | Künstliche antigen-spezifischen zellen und zugehörige verfahren | |
| TR200002731T2 (tr) | Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar | |
| DE3650184D1 (de) | Zellenfreier t-zellenantigenrezeptor und klinische verwendung. | |
| AR004545A1 (es) | Derivados de purin-6-ona, procedimientos para su preparacion, el uso de los mismos en la preparacion de medicamentos, medicamentos que los contieneny un procedimiento para preparar dichos medicamentos | |
| DE69734974D1 (de) | Verfahren zur transformation dendritischer zellen und aktivierung von t zellen | |
| CY1110235T1 (el) | Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων | |
| IL144265A0 (en) | Use of antibodies for the vaccination against cancer | |
| Slovin et al. | Immunological approaches for the treatment of prostate cancer | |
| UY26266A1 (es) | Antigeno asociado con tumores (r11) ley 17164 | |
| ATE226638T1 (de) | Retroviraler vektor und dessen verwendung in gentherapie | |
| ES2132027A1 (es) | Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante. | |
| ATE276364T1 (de) | Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren | |
| RU2000122041A (ru) | Способ лечения злокачественных опухолей головного мозга | |
| WO2000015767A3 (en) | Antigen-presenting cells and their use in therapy | |
| Truong | The effects of anti-La Crosse antibody and monoclonal antibodies against the G1 glycoprotein of La Crosse virus on the transcription step of the replication cycle. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |